Pharmaceutical industry research and development in europe

All new medicines introduced into the market are the result of lengthy, costly and risky research and development conducted by pharmaceutical companies:

  • 12 to 13 years

    Average time for a medicinal product to reach the market, since the first synthesis of the new active substance.

  • 1172 million

    The estimated cost of researching and developing a new chemical or biological entity in 2012.

    ($1506 million in 2011)

    (Mestre-ferrandiz et al, office of Health Economics, December 2012)

  • 2 out of 10 000

    Average substances in laboratories that will successfully pass all stages of development required to become a marketable medicine

Causes of death by major disease areas in europe

Data source: Eurostat, data relate to year 2010 (non-disease directly related causes of deaths: EFPIA calculations – percentages do not add due to rounding), April 2014

  • Diseases of the circulatory system
  • Malignant neoplasms
  • Diseases of the respiratory system
  • Diseases of the digestive system
  • Diseases of the nervous system and the sense organs
  • Endocrine, nutritional and metabolic diseases
  • Mental and behavioural disorders
  • Diseases of the genitourinary system
  • Certain infectious and parasitic
  • Diseases of the musculoskeletal system and connective tissues
  • Diseases of the blood(-forming organs) and immune mechanism disorders
  • Diseases of the skin and subcutaneous tissue
  • Others (Non-disease related causes of deaths)